|Description||AT101 acetic acid is orally bioavailable solvate of R-(-)-enantiomer of gossypol with potential antineoplastic activity. It is used as the treatment of non Hodgkin's lymphoma, prostate cancer, and non small cell cancer. It binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM. It induces apoptosis in vitro through activation of caspase-9. It delays onset of androgen-independent growth of VCaP prostate cancer xenografts in vivo. It was developed by Ascenta and in clinical phase 2.|
|Synonyms||(R)-(-)-Gossypol acetic acid;(-)-Gossypol acetic acid;(R)-Gossypol acetic acid;Acetic acid 7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde|
|Solubility||10 mM in DMSO|
|Application||AT101 acetic acid is used as the treatment of non Hodgkin's lymphoma, prostate cancer, and non small cell cancer.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||AT101 acetic acid was developed by Ascenta and in clinical phase 2.|
TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer mediated through a novel pathway involving inactivat...
Mcl1-IN-2, a hydroxyquinoline derivative, is an Mcl-1 inhibitor.
Venetoclax is a small-molecule inhibitor that has high selectivity for Bcl-2 (Ki < 0.01 nM in cell-free assays) over Mcl-1. It suppresses anti-apoptotic Bcl-2, ...
Spautin-1 is a potent and specific autophagy inhibitor, and inhibits the deubiquitinating activity of USP10 and USP13 with IC50 of ∼0.6-0.7 μM.
Marinopyrrole A, a new Mcl-1 inhibitor, could influence Mcl-1-Bim interaction and induce the degradation of Mcl-1 proteasomal and also lead to the apoptosis of ...
WEHI-539, a selective BCL-XL inhibitor that can be function as a single-agent inducer of apoptosis while sparing normal cells, it leads to MOMP and apoptosis du...
A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family member...
(+)-Apogossypol is a potent inhibitor of Bcl-2 family proteins, binding and inhibiting Bcl-2 and Bcl-X(L) with high affinity and induces apoptosis of tumor cell...
MIM1 is a small molecule inhibitor of Mcl-1 (IC50= 4.8 uM) by selectively targets the BH3-binding pocket.
AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM.
BDA-366 is a BCL2-BH4 antagonist(Ki=3.3nM) which suppresses human myeloma growth. BDA-366 induces apoptosis in MM cell lines and primary MM cells by inducing BC...
Mcl1-IN-1 is a potent Mcl-1-selective inhibitor with IC50 of 2.4 uM, relative to the related Bcl-2 family protein Bcl-xL.
FX1 is a selective inhibitor of B cell lymphoma 6 (BCL6) (IC50 = 35 μM in reporter assays), which can disrupt formation of the BCL6 repression complex, reactiva...
S-63845 is a selective inhibitor of MCL1 (Ki (MCL1, FP) < 1.2 nM; Kd (MCL1, SPR) = 0.19 nM; Ki (BCL2, FP) > 10.000 1.2 nM; Ki (BCL-XL, FP) > 10.000 1.2 nM). It ...
Gossypol Acetic Acid
The Acetate acid salt form of gossypol which may represent a promising new anticancer agent with a novel molecular mechanism and warrants further investigation ...
A-1331852, a substituted benzothiazole, is a high affinity BH3 mimetic Ligand of BCL protein BCL-XL (Ki≤ 10 pM). A-1331852 is an orally apoptosis-inducing agent...
Gambogic acid is a natural product inhibitor of Hsp90.
Pyridoclax, a pyridine derivative, has been found to be a Mcl-1 inhibitor that could induce apoptosis of cancer cells. IC50: 25 nM(Kd).